NLRP3 and breast cancer: NLRP3 expression was significantly inhibited dose-dependently by TQ in PBMCs of HR+ BC patients and TNBC patients, as summarized in Figure 8A. The aforementioned results came in accordance with those for A375 and B16F10 melanoma cells [101], where 5–20 μM of TQ significantly decreased NLRP3 expression in a dose-dependent manner [101].